Leukapheresis Market - Top Companies and Manufacturers

Companies Dominating the Leukapheresis Landscape

BioLineRx Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Gilead Sciences, Inc.
Haemonetics Corporation
Charles River Laboratories
Fresenius SE & Co.
StemExpress, LLC
AllCells, LLC
Cerus Corporation
Hemacare Corporation
Macopharma SA.

Browse Key Market Insights with Data Illustration:

Leukapheresis Market Size & Share, Forecast Report 2036

In the News

The U.S. Food and Drug Administration (FDA) has approved APHEXDATM (motixafortide) in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. BioLineRx Ltd., a commercial-stage biopharmaceutical company focused on certain cancers and rare diseases. Subcutaneous usage of APHEXDA is achieved through injectable administration.
Kite, a Gilead Company (Nasdaq: GILD), announced that the FDA in the United States authorized a modification to the manufacturing process that will shorten the manufacturing time for Yescarta® (axicabtagene ciloleucel). It is estimated that Kite's median turnaround time (TAT) in the United States will drop from 16 days to 14 days with this approval. The time interval between leukapheresis, the collection of a patient's T cells, and product release is known as the median TAT. Manufacturing is a crucial phase in this process that gets a patient's cells ready for a unique one-time cell therapy injection.

Frequently Asked Questions (FAQ)

Growing demand for leukopaks in clinical research, growing cases of blood-related disorders, and increasing clinical trials for CAR T-cell Therapy are the major factors driving the growth of the leukapheresis market.

The market size of leukapheresis is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024 -2036.

The major players in the market are BioLineRx Ltd., Gilead Sciences, Inc., Haemonetics Corporation, Charles River Laboratories, Fresenius SE & Co., StemExpress, LLC, AllCells, LLC, Cerus Corporation, Hemacare Corporation, Macopharma SA., and others.

The therapeutic segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Leukapheresis Market - Top Companies and Manufacturers

Companies Dominating the Leukapheresis Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the leukapheresis market?

What would be the CAGR of the leukapheresis market over the forecast period?

Who are the major players dominating the leukapheresis market?

Which segment captures the largest market size in the application segment in the leukapheresis market?

Which region will provide more business opportunities for the growth of the leukapheresis market in the future?